Reckitt Benckiser Group Pays $700 M to Settle Allegations of Improper Marketing and Sale of Suboxone


AG Aaron M. Frey.

Maine will receive approximately $5 M as the consequences of a settlement with the pharamaceutical distribution Reckitt Benckiser Group.  The announcement was made two days ago by Maine’s Attorney General Aaron M. Frey.

The settlement alleges the company, either directly or through a subsidiary, improperly marketed and otherwise promoted the drug Suboxone, resulting in improper expenditures of state Medicaid funds.

“The opioid crisis is one of the biggest challenges facing our state, so allegations that a company would improperly market Su boxone outside of a complete treatment plan are concerning,” said AG Frey in the press release.  “I applaud the work of our Medicaid Fraud Control Unit in assisting with this settlement agreement and recovering significant resources for the state.”

Reckitt is an English public limited company headquartered in Slough, England, the United Kingdom.